Jennifer Altomonte
Overview
Explore the profile of Jennifer Altomonte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1825
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Neumeyer V, Chavan P, Steiger K, Ebert O, Altomonte J
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941881
As the mechanisms underlying tumorigenesis become better understood, the dynamic roles of cellular components of the tumor microenvironment, and their cross-talk with tumor cells, have come to light as key...
2.
Rothfuss C, Baumann T, Donakonda S, Brauchle B, Marcinek A, Urban C, et al.
Blood
. 2025 Jan;
PMID: 39840945
Loss of anticancer NK cell function in AML patients is associated with fatal disease progression and remains poorly understood. Here, we demonstrate that AML-blasts isolated from patients rapidly inhibit NK...
3.
Glauss S, Neumeyer V, Hanesch L, Marek J, Hartmann N, Wiedemann G, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39410025
Background/objectives: Oncolytic virotherapy is a promising approach in cancer immunotherapy. We have previously described a recombinant hybrid oncolytic virus (OV), VSV-NDV, which has a favorable safety profile and therapeutic immunogenicity,...
4.
Gobel S, Pelz L, Silva C, Bruhlmann B, Hill C, Altomonte J, et al.
Appl Microbiol Biotechnol
. 2024 Feb;
108(1):240.
PMID: 38413399
Cell culture-based production of vector-based vaccines and virotherapeutics is of increasing interest. The vectors used not only retain their ability to infect cells but also induce robust immune responses. Using...
5.
Marek J, Hanesch L, Krabbe T, El Khawanky N, Heidegger S, Altomonte J
Mol Ther Oncolytics
. 2023 Sep;
30:117-131.
PMID: 37654972
Unraveling the complexities of the tumor microenvironment (TME) and its correlation with responsiveness to immunotherapy has become a main focus in overcoming resistance to such treatments. Targeting tumor-intrinsic retinoic acid-inducible...
6.
Gobel S, Jaen K, Fernandes R, Reiter M, Altomonte J, Reichl U, et al.
Biotechnol Bioeng
. 2023 Aug;
120(11):3335-3346.
PMID: 37584190
The development of efficient processes for the production of oncolytic viruses (OV) plays a crucial role regarding the clinical success of virotherapy. Although many different OV platforms are currently under...
7.
Gobel S, Jaen K, Dorn M, Neumeyer V, Jordan I, Sandig V, et al.
Biotechnol Bioeng
. 2023 Feb;
120(9):2639-2657.
PMID: 36779302
We present a proof-of-concept study for production of a recombinant vesicular stomatitis virus (rVSV)-based fusogenic oncolytic virus (OV), rVSV-Newcastle disease virus (NDV), at high cell densities (HCD). Based on comprehensive...
8.
Gobel S, Kortum F, Chavez K, Jordan I, Sandig V, Reichl U, et al.
Appl Microbiol Biotechnol
. 2022 Jun;
106(13-16):4945-4961.
PMID: 35767011
Oncolytic viruses (OVs) represent a novel class of immunotherapeutics under development for the treatment of cancers. OVs that express a cognate or transgenic fusion protein is particularly promising as their...
9.
Reale A, Calistri A, Altomonte J
Pharmaceutics
. 2021 Dec;
13(12).
PMID: 34959474
Oncolytic viruses (OVs) are an emerging class of therapeutics which combine multiple mechanisms of action, including direct cancer cell-killing, immunotherapy and gene therapy. A growing number of clinical trials have...
10.
Nettelbeck D, Leber M, Altomonte J, Angelova A, Beil J, Berchtold S, et al.
Viruses
. 2021 Aug;
13(8).
PMID: 34452286
Virotherapy research involves the development, exploration, and application of oncolytic viruses that combine direct killing of cancer cells by viral infection, replication, and spread (oncolysis) with indirect killing by induction...